LEO Pharma

LEO PHARMA LAUNCHES AD DAYS AROUND THE WORLD CAMPAIGN TO RAISE AWARENESS OF THE IMPACT OF ATOPIC DERMATITIS ACROSS CULTURES

Share
• In partnership with Global patient advocate Ashley Ann Lora, AD Days Around the World explores the impact of atopic dermatitis (AD) on the lives of individuals around the world living with this chronic and debilitating skin disease • The campaign features the emotional journey of four patient advocates from France, Italy, Germany and Spain and showcases the impact that AD has on people, regardless of culture or geography

BALLERUP, Denmark, 3 October 2022– LEO Pharma A/S, a global leader in medical dermatology, today launched AD Days Around the World, a global disease awareness campaign that highlights the experiences of people living with atopic dermatitis (AD) – the most common form of eczema.1 In collaboration with patient advocacy organizations in France, Italy, Germany and Spain, the campaign shares real patient stories to educate and inform people living with AD that regardless of nationality or culture, there is hope to triumph over adversity, despite common everyday challenges.

The campaign features Global patient advocate Ashley Ann Lora, who travels from the United States to France, Italy, Germany and Spain to meet with and document the emotionally compelling stories of four women – Marjolaine, Laura, Julia and África – who are living with AD, each at a different stage in their life. Through in-depth interviews, the documentary-style videos show audiences what it is like to live with and navigate the challenges associated with AD, and showcase how each of these resilient women has found peace, joy and empowerment over time. Their shared experiences and advice are as inspirational as they are informative.

“People don’t see eczema as a big deal, but it can cause so much suffering,” explained Ashley Ann Lora. “My hope is that the experiences shared through these stories will help people living with AD feel seen, heard and connected to others around the world with this condition. I also hope these personal stories help others gain a better understanding of their own eczema and their relationship with this condition. People living with AD don’t have to suffer; there are resources to help manage the condition and ways to enjoy life alongside it.”

“Atopic dermatitis is about more than just skin, and you never know where you might find your healing. For me, discovering dance and movement therapy transformed the way I see my eczema and today is a very important part of how I manage my condition,” said Marjolaine, a patient advocate living in France. “It is not one size fits all and different things will work for different people. I hope that my story will help others battling with atopic dermatitis to find what works for them.” 

The campaign offers access to these inspiring stories through www.ADDaysAroundTheWorld.com. Patients living with AD can watch the full video series featuring each patient advocate, learn more about AD, download a discussion guide to help facilitate better conversations with their healthcare professionals and access information about local patient advocacy organizations in each country.

“LEO Pharma is proud to have the opportunity to work with these inspiring patient advocates on AD Days Around the World. We know dermatology goes beyond the skin, and in our industry, we have the responsibility to see the whole patient when it comes to care,” said Christophe Bourdon Chief Executive Officer, LEO Pharma A/S.“Our hope is that through this campaign, and the inspiring stories of África, Laura, Julia and Marjolaine, other people living with AD realize there is life beyond an AD diagnosis and resources available to help them manage their skin condition.”

About atopic dermatitis

Atopic dermatitis is a chronic, inflammatory skin disease characterized by intense itch and eczematous lesions.2 Atopic dermatitis is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.3

 

About Ashley Ann Lora

Global patient advocate and campaign host Ashley Ann Lora has been living with AD for more than 25 years. As a passionate global advocate, she uses the power of vulnerability to speak up for patients and advises on the needs of the AD community. Through her social platform, she is able to connect with others to share her journey of living with AD and provide hope and optimism for others.

- - - 

References

  1. National Eczema Association. What is atopic dermatitis? https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis/ 
  2. Weidinger S, et al. Atopic dermatitis. Lancet. 2016;387(10023):1109–1122.
  3. Boguniewicz M, et al. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233–246.

Contacts

Contact:
David Patti
LEO Pharma, Global Product Communications
+1 973 796 7706
DAPAI@leo-pharma.com


Jes Broe Frederiksen
LEO Pharma, Global Product Communications
+45 53 60 59 48
JEBFE@leo-pharma.com

About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO Pharma

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,200 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

LEO Pharma closes deal for Spevigo®1.10.2025 09:00:00 CEST | Pressemeddelelse

Adding Spevigo® is a significant step forward in LEO Pharma’s focused growth strategy, to accelerate and expand patients’ access to treatments for medical dermatological conditions, including generalized pustular psoriasis (GPP), a rare and severe skin condition Spevigo® (spesolimab) is a first-in-class IL-36R antagonist successfully developed and launched by Boehringer Ingelheim and approved globally for the treatment and prevention of GPP flares Spesolimab is also being investigated for the treatment of other IL-36-mediated skin diseases

LEO Pharma Presents Late-Breaking Data at EADV 2025 Showing Week 16 Tralokinumab Response Predicts Long-Term Response in Moderate-to-Severe Atopic Dermatitis19.9.2025 16:00:00 CEST | Pressemeddelelse

Late-breaking data from the ECZTEND trial show that patients with moderate-to-severe atopic dermatitis (AD), who responded to Adtralza® (tralokinumab) / Adbry® (tralokinumab-ldrm) at Week 16, maintained stable, optimal treatment outcomes for up to three years.1 Additional data presented at EADV from the real-world TRACE study further support the long-term use of tralokinumab, with sustained improvements in disease severity, quality of life, sleep, and work productivity observed over 12 months of treatment.2-4 Presented as part of LEO Pharma’s most ambitious scientific program to date at the 2025 EADV Congress, the tralokinumab data reinforce the company’s leadership in medical dermatology and its commitment to advancing innovation across its biologics’ portfolio.

LEO Pharma Presents Late-Breaking Phase 3 Delgocitinib Cream Data in Adolescents with Moderate to Severe Chronic Hand Eczema (CHE)18.9.2025 15:45:00 CEST | Pressemeddelelse

The first late-breaking presentation was the phase 3 trial results for DELTA TEEN, showing delgocitinib cream had superior efficacy compared to cream vehicle and was generally well tolerated in adolescents, aged 12-17, with moderate to severe Chronic Hand Eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.1 In a second late-breaking presentation, pooled data from five phase 2b and phase 3 trials of delgocitinib cream confirmed a consistent safety profile for the treatment of moderate to severe CHE in adults.2 Fifteen other pieces of delgocitinib cream research formed part of LEO Pharma’s most ambitious scientific program to date at EADV 2025.3-17

LEO Pharma presents two late-breaking abstracts for temtokibart reporting positive Phase 2b efficacy, safety and biomarker results in moderate-to-severe atopic dermatitis at the 2025 EADV Annual Meeting in Paris17.9.2025 16:00:00 CEST | Pressemeddelelse

Results presented at EADV 2025 demonstrated that investigational agent temtokibart met its primary endpoint of percentage change in the Eczema Area and Severity Index (EASI) compared with placebo for the three highest doses (600 mg, 450 mg, and 300 mg).1 Significantly greater improvements in EASI were reported as early as Week 1 for temtokibart 450mg and 300mg, and Week 2 for 600mg, vs placebo; these results were maintained up to Week 32 in 600mg and 300mg arms, despite no treatment after Week 14.1 Safety analyses revealed that temtokibart was well-tolerated with no dose-dependent AEs, a low incidence of conjunctivitis, and no signal for herpes.1

LEO Pharma Takes Centre Stage With its Largest-Ever Scientific Programme at EADV 202515.9.2025 15:00:00 CEST | Pressemeddelelse

For the second year in a row, LEO Pharma delivers its largest and most ambitious scientific programme ever at the 2025 European Academy of Dermatology and Venereology (EADV), setting a new standard by presenting an unprecedented volume of scientific content for the company, with 5 late-breaking presentations and 24 regular abstracts.1-29 LEO Pharma’s scientific programme at EADV 2025 spans multiple dermatological indications, mirroring the company’s strong commitment to addressing both the most prevalent chronic skin diseases and hard-to-treat conditions.1-29 Highlights from EADV 2025 includes exciting phase 3 data in biologic injectables as well as foam and cream formulations, illustrating the breadth of therapeutic approaches represented in LEO Pharma’s medical dermatology portfolio.1-29

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye